APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.
- Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.
- Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
- SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
- Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.